Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV„ÄÅLarge Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.
Immunotherapy Gastrict Cancer
DRUG: Tislelizumab|DRUG: apatinib|DRUG: oxaliplatin|DRUG: S-1
Pathological complete response, Total tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell, 4 weeks after surgery
Major pathological response, Total/moderate tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell, 4 weeks after surgery|Objective Response Rate (ORR), Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor, At the end of Cycle 3 (each cycle is 21 days)]
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.